Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Lyell Immunopharma, Inc.
| Metric | Lyell Immunopharma, Inc. LYELHealthcare |
|---|---|
| Quality Score | 42 / 100 |
| Revenue (latest) | $36,000 |
| Net income (latest) | −$274M |
| Operating margin | −748344.4% |
| Net margin | −762355.6% |
| Return on equity | −110.6% |
| Return on assets | −80.7% |
| Return on capital (ROCE) | −92.7% |
| Debt / equity | 0.37× |
| Revenue growth (YoY) | −41.0% |
| Altman Z″ (distress) | -13.93 |
| Accruals / assets | −36.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.